FibroScan® is now available in 11 United Digestive clinics, improving early detection and care for liver disease WESTBOROUGH, Mass., July 15, 2025 /PRNewswire/ -- Echosens, the leader in non-invasive liver diagnostics, has partnered with United Digestive, the largest gastroenterology platform in the Southeast, to bring FibroScan® to 11 clinics across Georgia and Florida. This collaboration enhances United Digestive's ability to detect liver disease earlier and develop tailored care plans based o

REDWOOD CITY, CA, USA I July 14, 2025 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant o

INGELHEIM, Germany & BALLERUP, Denmark I July 14, 2025 I Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and transfer agreement to commercialize and advance the development of SPEVIGO ® (spesolimab). SPEVIGO ® is an innovative, humanized, and selective monoclonal antibody that targets and blocks the activation of the interleukin-36 (IL-36) receptor – a key signaling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases, i

Rahway: Merck, known as MSD in India, is set to begin Phase 3 trials to evaluate the safety and efficacy of 'MK-8527', an investigational once-monthly, oral drug indicated for HIV. In collaboration with the Gates Foundation, the EXPrESSIVE-10 (MK-8527-010) trial will evaluate the safety and efficacy of MK-8527 in women and adolescent girls in 16 countries across sub-Saharan Africa and will begin enrolling in August 2025. The trial is sponsored by Merck and the trial conducting bodies, the Intern

JCR Pharmaceuticals inked a collaboration, option and license deal with Acumen Pharmaceuticals to develop an effective brain-penetrant biologic to treat Alzheimer's disease (AD).“By combining our J-Brain Cargo platform with Acumen’s novel, AβO-selective antibodies, we aim to overcome the challenge of delivering biologics to the brain, which has limited progress in treating neurodegenerative disease,” said Shin Ashida, chief executive of JCR.Under the terms of the agreement announced Tuesday, JCR

The UK's National Institute for Health and Care Excellence (NICE) issued final draft guidance recommending Vertex Pharmaceuticals’ cystic fibrosis (CF) oral triple therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor).Under an expanded access agreement between Vertex and NHS England, the once-daily combination will be offered to all eligible individuals with CF aged 6 and older harbouring at least one F508del mutation or another responsive mutation in the CFTR gene — as an alternative to the c

Acadia CEO Catherine Owen Adams, Acadia Pharmaceuticals More than thirty years since its 1993 founding, Catherine Owen Adams and Elizabeth Thompson—the R&D combo that has led Acadia since last summer—are managing two products on the market and a pipeline estimated to be worth an additional $12 billion in sales. After 32 years in business, Acadia Pharmaceuticals recently held its first-ever R&D Day, forecasting a potential $12 billion in annual sales stemming from its investigational pipeline. “W

NEWS - 15 July, 2025 - Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, is pleased to announce that it has been selected for the third round of the Ministry of Economy, Trade and Industry (METI) and the New Energy and Industrial Technology Development Organization (NEDO)’s Generative AI Accelerator Challenge (GENIAC) project, which aims to strengthen domestic development capabilities in generative AI. Th

Thousands of women who undergo radiotherapy for low-risk breast cancer could be spared some of the side effects of treatment after a study confirmed that more targeted treatments are just as effective at controlling the disease in the long term. Findings of the IMPORT LOW trial, which was led by The Institute of Cancer Research, London, and the University of Cambridge, have shown that limiting radiation to only the tumour area is just as effective as treating the whole breast, therefore reducing

RSS Otsuka Pharmaceutical Co., Ltd. (Otsuka) has entered into an asset purchase agreement with Cantargia AB (Cantargia) for the acquisition of assets related to CAN10. CAN10 is an IL-1RAP antibody in development as a drug candidate for the treatment of autoimmune diseases. Through the transaction, Otsuka will acquire the exclusive global rights to develop, manufacture, and commercialize CAN10 and associated assets. CAN10 is a monoclonal antibody that targets IL-1RAP (Interleukin-1 Receptor Acces